BBIO 241220 20.00P (BBIO241220P20000) Stock Options, News & Quotes

US OptionsDetailed Quotes

BBIO241220P20000

Watchlist

1.92
+0.02+1.05%

15min DelayClose Nov 22 15:59 ET

2.52High1.90Low

Intraday

5D
Daily

News

BridgeBio Pharma : FDA Approves Heart Disease Drug 'Acoramidis'
RTTNewsNov 23 20:07 ET
Express News | BridgeBio Pharma Inc - Grants Bayer Rights to Commercialize Acoramidis in Europe
ReutersNov 22 19:12 ET
Express News | BridgeBio Pharma Inc - to Receive $500 Million Payment Under Royalty Agreement
ReutersNov 22 19:12 ET
Express News | BridgeBio Pharma Inc - FDA Approves Attruby for Treatment of Attr-Cm
ReutersNov 22 19:11 ET
Express News | Attruby™ (Acoramidis), a Near Complete Ttr Stabilizer (≥90%), Approved by FDA to Reduce Cardiovascular Death and Cardiovascular-Related Hospitalization in Attr-Cm Patients
ReutersNov 22 19:11 ET
BridgeBio Pharma Trading Halted, News Pending
TipRanksNov 22 16:10 ET

Comments

Jaguar8

10 minutes ago

My Monday Watchlist. These are the stocks with POSSIBLE run between 20% and up based on news, chart, or promotion.

I will update it later if i find more.
I see more Quantum play this week.
$Quantum (QMCO.US)$ AWS launched QuantumEmbark. Up after hours. Small float. 0 shares LTB.
$Arqit Quantum (ARQQ.US)$ AWS launched Quantum Embark.Increased market cap which translates to stock increasing in stock value and increased confidence in the stock. Low float. Up after hours.
$D-Wave Quantum (QBTS.US)$ AWS...

Jaguar8

Nov 22 19:28

Definitely on watch Monday. FDA approval for reducing cardiovascular death & hospitalizations. Will receive $500M as royalty funding agreement. Bayer granted rights to commercialize in Europe. BIG!

$BridgeBio Pharma (BBIO.US)$

Jaguar8

Nov 22 19:06

NEWS

$BridgeBio Pharma (BBIO.US)$
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
BridgeBio Pharma announced FDA approval of Attruby™ (acoramidis) for treating adults with ATTR-CM to reduce cardiovascular death and hospitalization.
The approval is based on the ATTRibute-CM Phase 3 study results, showing a 42% reduction in composite all-cause mortality and recurrent cardiovasc...

Trytosaveabit

Nov 22 18:42

T 1 News Halt!

$BridgeBio Pharma (BBIO.US)$ Reuters
28 mins ago
Attruby™ (Acoramidis), a Near Complete Ttr Stabilizer (≥90%), Approved by FDA to Reduce Cardiovascular Death and Cardiovascular-Related Hospitalization in Attr-Cm Patients
BridgeBio Pharma Inc - to Receive $500 Million Payment Under Royalty Agreement
BridgeBio Pharma Inc - Grants Bayer Rights to Commercialize Acoramidis in Europe

Stock_Drift

Feb 2 04:12

$AstraZeneca (AZN.US)$ $BridgeBio Pharma (BBIO.US)$ $ASTRAZENECA PLC (AZNCF.US)$
📊⚡️📊

AstraZeneca's Results From Japan Phase 3 Trial Of Acoramidis For Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) Is Consistent With BridgeBio Pharma's ATTRibute-CM Phase 3 Trial, Including Survival, Cardiac-Related Hospitalizations